You are here
The Award database is continually updated throughout the year. As a result, data for FY22 is not expected to be complete until September, 2023.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
MK III Upper Extremity ExoskeletonSBC: Ekso Bionics Inc Topic: 739552
As the carry and protective gear of the modern war fighter increases, the burden on the human body will necessarily increase. In our present TALOS MkIII project, we are developing lower body augmentation to preserve speed and agility while bearing this weight. Yet we cannot ignore the impact of this weight on the upper body: in this project we propose to develop an upper body exoskeleton with p ...STTR Phase II 2015 Department of DefenseSpecial Operations Command
Human Performance Optimization: Ketone Esters for Optimization of Operator Performance in HypoxiaSBC: HVMN Inc. Topic: SOCOM17C001
In the setting of altitude-induced hypoxia, operator cognitive capacity degrades and can compromise both individual and team performance. This degradation is linked to falling brain energy (ATP) levels and an increased reliance on anaerobic energy production from glucose. Ketone bodies are the evolutionary alternative substrate to glucose for brain metabolic requirements; previous studies have sho ...STTR Phase I 2018 Department of DefenseSpecial Operations Command
Marburg Virus Prophylactic Medical CountermeasureSBC: Flow Pharma, Inc. Topic: CBD18A002
Flow Pharma, Inc. is a biotechnology company in the San Francisco Bay Area developing fully synthetic cytotoxic T lymphocyte (CTL)stimulating peptide vaccines for Marburg virus. The FlowVax vaccine platform allows us to create dry powder formulations of biodegradablemicrospheres and TLR adjuvants incorporating class I and class II T cell epitopes. FlowVax vaccines can be designed for delivery by i ...STTR Phase I 2018 Department of DefenseOffice for Chemical and Biological Defense
Marburg Virus Prophylactic Medical CountermeasureSBC: MAPP BIOPHARMACEUTICAL, INC. Topic: CBD18A002
There are currently no vaccines or therapeutics available for Marburg Virus Disease (MVD). Given the specter of weaponization and the terriblemorbidity and high mortality rate of MVD, this represents a critical threat to the operational readiness of the Warfighter. While traditionalvaccines have proven to be a huge contribution to public health, they do have some limitations especially in the cont ...STTR Phase I 2018 Department of DefenseOffice for Chemical and Biological Defense